[Misleading advertisement of Adalat Oros].
Referring to the INSIGHT trial published in The Lancet, Bayer Netherlands states in an advertisement in Dutch medical journals that nifedipine reduces cardiovascular events by 50% in patients with hypertension and at least one additional risk factor. However, the agent studied in the INSIGHT trial did not reduce cardiovascular events in comparison to treatment with a diuretic. On the contrary, the incidence of myocardial infarction increased (fatal infarction even increased significantly), and the risk of stroke was not significantly reduced. Therefore the advertisement is misleading.
Verheugt
F W
FW
Academisch Ziekenhuis St Radboud, afd. Cardiologie, Postbus 9101, 6500 HB Nijmegen.
D000329:Advertising / Q000592:standards*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D008192:Deception; D004232:Diuretics / Q000627:therapeutic use; D004345:Drug Industry / Q000592:standards*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009426:Netherlands; D009543:Nifedipine / Q000627:therapeutic use*; D011643:Publishing / Q000592:standards; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D004232:Diuretics; D009543:Nifedipine